Molbio Diagnostics IPO Day 1 Subscription Reaches 0.34 Times as QIBs Lead Investor Demand
5paisa कॅपिटल लि
- 2 मिनिटांचे वाचन
अंतिम अपडेट: 10 ऑगस्ट 2026 - 04:29 pm
Molbio Diagnostics Limited's initial public offering (IPO) was subscribed 0.34 times by 5:24 PM on August 10, 2026. The public issue received bids for 27,37,620 shares against 81,58,529 shares available for subscription. The Qualified Institutional Buyers (QIBs) category led the demand with a subscription of 0.63 times, followed by the Employee (EMP) portion at 0.46 times, while the Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) portions were subscribed 0.24 times and 0.21 times, respectively.
भारतीय मार्केटमध्ये इन्व्हेस्ट करा आणि 5paisa सह भविष्यातील क्षमता अनलॉक करा!Subscription Status of Molbio Diagnostics IPO
| तारीख | क्यूआयबी | एनआयआय | रिटेल | ईएमपी | एकूण |
|---|---|---|---|---|---|
| दिवस 1 (ऑगस्ट 10) | 0.63 | 0.24 | 0.21 | 0.46 | 0.34 |
Here are the subscription details for Molbio Diagnostics IPO Day 2, as of 5:24 PM:
| इन्व्हेस्टर कॅटेगरी | सबस्क्रिप्शन (वेळा) | ऑफर केलेले शेअर्स | यासाठी शेअर्स बिड | एकूण |
|---|---|---|---|---|
| अँकर | 1 | 34,87,717 | 34,87,717 | 281.459 |
| क्यूआयबी | 0.63 | 23,25,146 | 14,60,952 | 117.899 |
| एनआयआय | 0.24 | 17,43,859 | 4,15,764 | 33.552 |
| रिटेल | 0.21 | 40,69,004 | 8,51,364 | 343.641 |
| ईएमपी | 0.46 | 20,520 | 9,540 | 0.770 |
| एकूण | 0.34 | 81,58,529 |
27,37,620 |
820.244 |
मुख्य हायलाईट्स - दिवस 1
- Overall subscription stood at 0.34 times on Day 1 (August 10, 2026).
- पात्र संस्थात्मक खरेदीदार (QIBs) 0.63 वेळा सबस्क्राईब केले.
- नॉन-इन्स्टिट्यूशनल इन्व्हेस्टर्स (एनआयआय) ने 0.24 वेळा सबस्क्राईब केले.
- रिटेल इन्व्हेस्टर 0.21 वेळा सबस्क्राईब केले.
- Employee (EMP) portion subscribed 0.46 times.
- Anchor investors had fully subscribed their allocated portion before the issue opened, with 34,87,717 shares allotted.
- एकूणच IPO सुरुवातीच्या दिवशी 0.34 वेळा सबस्क्राईब झाला.
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
- मोफत IPO ॲप्लिकेशन
- सहजपणे अप्लाय करा
- IPO साठी पूर्व-अर्ज करा
- UPI बिड त्वरित
5paisa वर ट्रेंडिंग
5paisa कॅपिटल लि
अस्वीकृती: सिक्युरिटीज मार्केटमधील इन्व्हेस्टमेंट मार्केट रिस्कच्या अधीन आहेत, इन्व्हेस्टमेंट करण्यापूर्वी सर्व संबंधित डॉक्युमेंट्स काळजीपूर्वक वाचा. तपशीलवार अस्वीकृतीसाठी कृपया येथे क्लिक करा.